Corcept Faces Class Action Lawsuit Allegations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CORT?
Source: Globenewswire
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Corcept Therapeutics, representing stock purchasers from October 31, 2024, to December 30, 2025, alleging violations of the Securities Exchange Act by top executives.
- FDA Review Concerns: The lawsuit claims that Corcept misrepresented the status of its New Drug Application for relacorilant, asserting no issues with the FDA's review, while the FDA had repeatedly raised concerns about the adequacy of clinical evidence, significantly increasing the risk of non-approval.
- Stock Price Plunge: On December 31, 2025, Corcept revealed the FDA's Complete Response Letter regarding relacorilant, leading to a more than 50% drop in stock price, indicating strong market concerns about the company's future prospects.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act, any investor who purchased Corcept stock during the class period can seek to be appointed as lead plaintiff, representing other shareholders in pursuit of potential recovery, highlighting the importance of investor representation in securities fraud cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 34.240
Low
50.00
Averages
91.00
High
121.00
Current: 34.240
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Accused of Misleading Investors
- Class Action Filed: Robbins LLP has initiated a class action on behalf of all investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, alleging that the company misled investors regarding the viability of its new product candidate, potentially leading to significant investor losses.
- FDA Concerns: During the class period, Corcept claimed strong support for its New Drug Application (NDA) from the FDA; however, the FDA had raised concerns about the adequacy of clinical evidence, creating a material risk that the approval for relacorilant would not be granted, which was not disclosed to investors.
- Stock Price Plunge: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter (CRL), causing its stock price to plummet from $70.20 on December 30 to $34.80, a decline of 50.4%, directly impacting investor asset values.
- Legal Implications: Investors are eligible to participate in the class action against Corcept, with Robbins LLP offering contingency-based representation, aiming to help investors recover losses and improve corporate governance, demonstrating a strong commitment to holding executives accountable.
See More
Corcept Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Corcept Therapeutics, representing stock purchasers from October 31, 2024, to December 30, 2025, alleging violations of the Securities Exchange Act by top executives.
- FDA Review Concerns: The lawsuit claims that Corcept misrepresented the status of its New Drug Application for relacorilant, asserting no issues with the FDA's review, while the FDA had repeatedly raised concerns about the adequacy of clinical evidence, significantly increasing the risk of non-approval.
- Stock Price Plunge: On December 31, 2025, Corcept revealed the FDA's Complete Response Letter regarding relacorilant, leading to a more than 50% drop in stock price, indicating strong market concerns about the company's future prospects.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act, any investor who purchased Corcept stock during the class period can seek to be appointed as lead plaintiff, representing other shareholders in pursuit of potential recovery, highlighting the importance of investor representation in securities fraud cases.
See More
Corcept Loses Patent Appeal for Korlym, Shares Plunge
- Patent Litigation Outcome: The U.S. Court of Appeals upheld the New Jersey district court's ruling that Corcept failed to prove patent infringement, resulting in significant legal challenges that could impact the company's competitive position in the market.
- Stock Price Reaction: Following the ruling, Corcept's (CORT) shares plummeted by 15%, reflecting investor concerns about the company's future, especially as its Korlym product faces generic competition.
- Market Dynamics: While Corcept's stock declined, Teva Pharmaceuticals (TEVA) saw a slight increase in its share price, indicating a positive market reaction to Teva's victory in the patent dispute, which may enhance its market share.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around CORT stock shifted from 'bearish' to 'bullish' over the past 24 hours, with message volume increasing from 'extremely low' to 'high', indicating investor expectations for a potential rebound.
See More
Corcept Therapeutics Faces Significant Pressure as Shares Approach Lows
- Legal Ruling Impact: The appeals court upheld a ruling against Corcept, concluding that Teva's generic Korlym label would not lead doctors to follow patented dosing methods, weakening Corcept's patent protection and potentially exposing its flagship product to earlier competition, thereby increasing market uncertainty.
- Stock Price Decline: Corcept's shares are currently trading 24.4% below the 20-day simple moving average and 52.9% below the 100-day simple moving average, indicating a significant bearish trend, with a 57.55% decline over the past 12 months, positioning the stock closer to its 52-week lows, reflecting ongoing market weakness.
- Upcoming Earnings Report: Corcept is set to report earnings on February 24, with an estimated EPS of 31 cents (up from 26 cents) and revenue expected to reach $254.72 million (up from $181.89 million), indicating potential growth in revenue despite current challenges.
- Analyst Rating Changes: Despite facing challenges, Corcept's stock retains a Buy rating with an average price target of $100, with Canaccord Genuity and HC Wainwright & Co. raising their targets on January 23, reflecting analysts' confidence in the company's future performance.
See More
Corcept Therapeutics Shares Plunge Over 20% After Patent Ruling
- Patent Dispute Loss: Corcept Therapeutics' shares plummeted over 20% following a federal appeals court ruling against the company in a patent dispute with Israeli drugmaker Teva, highlighting the company's vulnerability in market competition.
- FDA Approval of Generic: Teva received FDA approval in August 2020 to market a generic version of Korlym, a once-daily oral medication for Cushing's syndrome, which intensifies the market pressure on Corcept.
- Court Ruling Impact: The U.S. Court of Appeals upheld the New Jersey District Court's ruling that Teva did not infringe Corcept's U.S. patents, indicating significant challenges for Corcept in protecting its intellectual property.
- Market Reaction: The sharp decline in Corcept's stock price reflects investor concerns about the company's future profitability, particularly in light of generic competition and setbacks in patent protection.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Corcept Therapeutics
- Investigation Launched: Pomerantz LLP is investigating claims of securities fraud against Corcept Therapeutics, focusing on whether the company and its executives engaged in unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- FDA Response: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter for relacorilant's New Drug Application, stating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness is required, indicating regulatory hurdles that may affect future drug approval.
- Stock Price Plunge: Following the FDA announcement, Corcept's stock price fell by $35.40, a 50.42% drop, closing at $34.80 per share, reflecting market pessimism regarding the company's prospects and potentially leading to significant investor losses.
- Legal Context: Pomerantz LLP, a prominent firm in securities class action litigation with over 85 years of experience, focuses on advocating for victims of securities fraud; if the investigation confirms fraudulent activities, it could trigger large-scale class action lawsuits, further impacting the company's reputation.
See More
Corcept Therapeutics Accused of Misleading Investors
- Class Action Filed: Robbins LLP has initiated a class action on behalf of all investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, alleging that the company misled investors regarding the viability of its new product candidate, potentially leading to significant investor losses.
- FDA Concerns: During the class period, Corcept claimed strong support for its New Drug Application (NDA) from the FDA; however, the FDA had raised concerns about the adequacy of clinical evidence, creating a material risk that the approval for relacorilant would not be granted, which was not disclosed to investors.
- Stock Price Plunge: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter (CRL), causing its stock price to plummet from $70.20 on December 30 to $34.80, a decline of 50.4%, directly impacting investor asset values.
- Legal Implications: Investors are eligible to participate in the class action against Corcept, with Robbins LLP offering contingency-based representation, aiming to help investors recover losses and improve corporate governance, demonstrating a strong commitment to holding executives accountable.
See More
Corcept Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Corcept Therapeutics, representing stock purchasers from October 31, 2024, to December 30, 2025, alleging violations of the Securities Exchange Act by top executives.
- FDA Review Concerns: The lawsuit claims that Corcept misrepresented the status of its New Drug Application for relacorilant, asserting no issues with the FDA's review, while the FDA had repeatedly raised concerns about the adequacy of clinical evidence, significantly increasing the risk of non-approval.
- Stock Price Plunge: On December 31, 2025, Corcept revealed the FDA's Complete Response Letter regarding relacorilant, leading to a more than 50% drop in stock price, indicating strong market concerns about the company's future prospects.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act, any investor who purchased Corcept stock during the class period can seek to be appointed as lead plaintiff, representing other shareholders in pursuit of potential recovery, highlighting the importance of investor representation in securities fraud cases.
See More
Corcept Loses Patent Appeal for Korlym, Shares Plunge
- Patent Litigation Outcome: The U.S. Court of Appeals upheld the New Jersey district court's ruling that Corcept failed to prove patent infringement, resulting in significant legal challenges that could impact the company's competitive position in the market.
- Stock Price Reaction: Following the ruling, Corcept's (CORT) shares plummeted by 15%, reflecting investor concerns about the company's future, especially as its Korlym product faces generic competition.
- Market Dynamics: While Corcept's stock declined, Teva Pharmaceuticals (TEVA) saw a slight increase in its share price, indicating a positive market reaction to Teva's victory in the patent dispute, which may enhance its market share.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around CORT stock shifted from 'bearish' to 'bullish' over the past 24 hours, with message volume increasing from 'extremely low' to 'high', indicating investor expectations for a potential rebound.
See More
Corcept Therapeutics Faces Significant Pressure as Shares Approach Lows
- Legal Ruling Impact: The appeals court upheld a ruling against Corcept, concluding that Teva's generic Korlym label would not lead doctors to follow patented dosing methods, weakening Corcept's patent protection and potentially exposing its flagship product to earlier competition, thereby increasing market uncertainty.
- Stock Price Decline: Corcept's shares are currently trading 24.4% below the 20-day simple moving average and 52.9% below the 100-day simple moving average, indicating a significant bearish trend, with a 57.55% decline over the past 12 months, positioning the stock closer to its 52-week lows, reflecting ongoing market weakness.
- Upcoming Earnings Report: Corcept is set to report earnings on February 24, with an estimated EPS of 31 cents (up from 26 cents) and revenue expected to reach $254.72 million (up from $181.89 million), indicating potential growth in revenue despite current challenges.
- Analyst Rating Changes: Despite facing challenges, Corcept's stock retains a Buy rating with an average price target of $100, with Canaccord Genuity and HC Wainwright & Co. raising their targets on January 23, reflecting analysts' confidence in the company's future performance.
See More
Corcept Therapeutics Shares Plunge Over 20% After Patent Ruling
- Patent Dispute Loss: Corcept Therapeutics' shares plummeted over 20% following a federal appeals court ruling against the company in a patent dispute with Israeli drugmaker Teva, highlighting the company's vulnerability in market competition.
- FDA Approval of Generic: Teva received FDA approval in August 2020 to market a generic version of Korlym, a once-daily oral medication for Cushing's syndrome, which intensifies the market pressure on Corcept.
- Court Ruling Impact: The U.S. Court of Appeals upheld the New Jersey District Court's ruling that Teva did not infringe Corcept's U.S. patents, indicating significant challenges for Corcept in protecting its intellectual property.
- Market Reaction: The sharp decline in Corcept's stock price reflects investor concerns about the company's future profitability, particularly in light of generic competition and setbacks in patent protection.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Corcept Therapeutics
- Investigation Launched: Pomerantz LLP is investigating claims of securities fraud against Corcept Therapeutics, focusing on whether the company and its executives engaged in unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- FDA Response: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter for relacorilant's New Drug Application, stating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness is required, indicating regulatory hurdles that may affect future drug approval.
- Stock Price Plunge: Following the FDA announcement, Corcept's stock price fell by $35.40, a 50.42% drop, closing at $34.80 per share, reflecting market pessimism regarding the company's prospects and potentially leading to significant investor losses.
- Legal Context: Pomerantz LLP, a prominent firm in securities class action litigation with over 85 years of experience, focuses on advocating for victims of securities fraud; if the investigation confirms fraudulent activities, it could trigger large-scale class action lawsuits, further impacting the company's reputation.
See More
